PathAI Diagnostics, a leading laboratory services company, today announced the world's first AI-Assisted Laboratory Developed Test (LDT) for the histologic scoring and staging of metabolic dysfunction-associated steatotic liver disease (MASLD) and metabolic dysfunction-associated steatohepatitis (MASH). This pioneering advancement will be introduced at the American College of Gastroenterology 2023 (ACG2023) Meeting in Vancouver, Canada, from October 20-25.
MASLD and MASH are posing an escalating healthcare challenge, affecting millions of individuals worldwide. Recent estimates suggest that approximately 37.8% of the global adult population suffers from some form of MASLD, with 5-6% of the U.S. adult population at risk of progressing to MASHa potential precursor to severe conditions such as cirrhosis and liver cancer.1-3
While the gold standard for MASLD/MASH scoring is liver biopsy, the scoring provided by pathologists can exhibit variability.4-5 In fact, there can be as much as a 30% disagreement in MASH diagnosis between pathologists, and intra-observer variability can reach up to 41% for the same case.6 Accurate scoring and staging are paramount, as each fibrosis stage corresponds to approximately a two-fold increase in liver-related mortality.7
In order to better tackle this growing issue, PathAI Diagnostics developed AI.Dx MASH, a laboratory developed test, which provides AI-assisted histologic scoring that supports expert pathologists with enhanced insights for liver biopsy reporting. "We are excited to bring the world's first AI-assisted Laboratory Developed Test for MASH to market, said Jim Sweeney, President of PathAI Diagnostics. The tool uses our deep expertise in AI-powered pathology coupled with our world-class diagnostics laboratory to improve patient outcomes through AI-assisted histologic scoring for MASH."
This groundbreaking tool utilizes an AI algorithm that has been proven to significantly reduce inter- and intra-operator variability in CRN scoring. Moreover, AI.Dx MASH reports include image overlays and quantitation, offering a comprehensive view of steatosis, lobular inflammation, hepatocyte ballooning, and fibrosis, thus facilitating more accurate diagnosis and staging.8-11
AI.Dx MASH provides a powerful tool for histologic MASH scoring by offering visual image overlays of key features to show how a score was reached, said R. Shawn Kinsey, MD, gastrointestinal and hepatobiliary pathologist at PathAI Diagnostics. This addresses one of the key challenges that leads to variability when assessing progression of the disease for a more accurate summary of a patients condition to inform future treatment and intervention.
Learn more about AI.Dx MASH and PathAI Diagnostics at Booth 613 at the 2023 American College of Gastroenterologists Meeting in Vancouver, Canada, October 20-25. Alternatively, explore PathAI Diagnostics full range of anatomic and molecular pathology services, spanning gastroenterology, dermatology, urology, and women's health, at www.pathaidx.com.
About PathAI Diagnostics
PathAI Diagnostics, formerly Poplar Healthcare, is a leading laboratory services company based in Memphis, TN, pioneering digital pathology and serving a nationwide client base of gastroenterologists, dermatologists, oncologists, urologists and gynecologists.
SVM Public Relations and Marketing Communications
View source version on newsdirect.com: https://newsdirect.com/news/pathai-diagnostics-unveils-worlds-first-ai-assisted-laboratory-developed-test-for-masld-and-mash-448837860
Disclaimer: The views, suggestions, and opinions expressed here are the sole responsibility of the experts. No journalist was involved in the writing and production of this article.